Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 8 de 8 
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020;395:11 de enero. [Ref.ID 103504]
2.Tiene citas relacionadas Cita con resumen
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, Jackisch C, de Azambuja E, Procter M, Suter TM, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8. [Ref.ID 96181]
3.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Bonanni B, Constantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data1827-1834. Lancet 2013;381:1827-34. [Ref.ID 95506]
4. Cita con resumen
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JMS, Ellis I, Peckitt C, Hall E, Bliss JM, for the TACT Trial Management Group and the TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92. [Ref.ID 85871]
5.Tiene citas relacionadas Cita con resumen
Smith I, Procter M, Gelber RD, Guillaume S, Feyereisolva A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, López RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, for the HERA study team. 2-year follow-up trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36. [Ref.ID 78796]
6. Cita con resumen
Dowsett M, Ashworth A. New biology of the oestrogen receptor. Lancet 2003;362:260-2. [Ref.ID 66955]
7.
Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42. [Ref.ID 66556]
8.Tiene citas relacionadas
Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention Trial. Lancet 1998;352:98-101. [Ref.ID 39510]
Seleccionar todas
 
 1 a 8 de 8